Skip to content

Performance of an Ultrasensible Malaria Rapid Diagnostic Test Among Pregnant Women in Burkina Faso

Evaluation of a Highly Sensitive Rapid Diagnostic Test for Detecting Falciparum Malaria Infection in Pregnancy in Burkina Faso

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06572644
Acronym
HS-RDT-MiP
Enrollment
288
Registered
2024-08-27
Start date
2022-10-11
Completion date
2023-12-31
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria,Falciparum

Keywords

Pregnancy, Malaria, Performance, Ultrasensible rapid diagnostic test, Burkina Faso

Brief summary

The goal of this observational study is to learn about the diagnostic performance of the highly sensitive rapid diagnostic test (HS-RDT) compared to an ultrasensitive qPCR for detection of falciparum malaria in pregnant women attending antenal care (ANC) in Burkina Faso. The main question it aims to answer is: • What are the sensitivity and specificity of the HS-RDT compared to ultrasensitive quantitative polymerase chain reaction (qPCR) considered as gold standard for dection of falciparum malaria in pregnant women attending ANC in Burkina Faso ? Participants will be included during their ANC visits and screened for malaria using the HS\_RDT, the conventional RDT (Co\_RDT), microscopy, and qPCR.

Detailed description

A cross-sectional study including 288 pregnant women was conducted at the Centre médical urbain (CMU) of Lafiabougou located in the periurban area of Bobo-Dioulasso the second largest city of Burkina Faso. Pregnant women attending their ANC visits at the CMU of Lafiabougou were recruited and enrolled into the study if eligible criteria were fulfilled. At enrolment, an individual structured questionnaire was administered to the selected pregnant women and their sociodemographic data (age, educational level, and profession) and history of illness was collected. In addition, obstetric history (parity, gestational age, number of ANC visits, uptake of IPTp-SP) and clinical information (body temperature, weight, height, and arm circumference) were recorded. Thereafter, a venous blood sample (5 mL) was collected to screen for malaria infection (based on HS-RDT, Co\_RDT, and thick and thin blood smears), dried blood spots (DBS) (for molecular studies), and haemoglobin concentration measurement. The remaining blood sample was stored for future studies. After enrolment, only pregnant women eligible for their first IPTp-SP dose uptake was followed up for 30 days to assess the impact of IPTp-SP on both falciparum parasitaemia and falciparum resistant strains. At the end of follow up, a venous blood sample (5 mL) was collected for thick and thin blood smears, DBS, and haemoglobin concentration measurement. The remaining blood sample was stored for future studies. All biological samples was collected and stored at ambient temperature before being transported to the Laboratory of Parasitology of Centre MURAZ and processed. The index tests included HS\_RDT (NxTek Eliminate Malaria Pf, product code 05FK140, batch No. 05LDG008B, Alere/Abbott, Republic of Korea), Co\_RDT (AdvDxTM Malaria Pf, product code 004ADFEF025KI-2, batch No. ADF77/0222, Advy Chemical, India), and light microscopy. The ultrasensitive qPCR assay targeting the multicopy conserved var gene acidic terminal sequence (varATS) (Hofmann et al. 2015) was used as gold standard.

Interventions

None listed

Sponsors

University of Ghana
CollaboratorOTHER
Centre MURAZ/Institut National de Santé Publique
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Living in Bobo-Dioulasso for at least 6 months before the beginning of the study ; * Provision of informed consent.

Exclusion criteria

* Past history of malaria or antimalarial drugs within the last 3 months ; * Having tested positive for malaria by microscopy or RDT in any previous ANC visit ; * Symptoms and signs of severe malaria as defined by WHO.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of HS_RDTAt baselineIt is defined as the proportion of positives that are correctly identified when compared with the gold standard (qPCR).
Specificity of HS_RDTAt baselineIt is defined as proportion of negatives that are correctly identified when compared with the gold standard (qPCR).

Secondary

MeasureTime frameDescription
Negative predictive valueAt baselineProbability that P. falciparum infection is not present when HS\_RDT, Co\_RDT, and microscopy are negative
Impact of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp- SP) on falciparum parasitaemia30 days after uptake of IPTp-SPProportion of pregnant women with falciparum parasitaemia 30 days after uptake of IPTp-SP
The prevalence of Pfhrp2 and Pfhrp3 genes deletions among the study participantsAt baselineProportion of pregnant women with malaria parasites carrying Pfhrp2/Pfhrp3 deletions
Positive predictive valueAt baselineProbability that P. falciparum infection is present when HS\_RDT, Co\_RDT, and microscopy are positive

Other

MeasureTime frameDescription
Prevalence of anaemiaAt baselineProportion of pregnant women with haemoglobin concentration \<11 g/dL
Prevalence of Pfdhfr & Pfhdps mutationsAt baselineProportion of pregnant women with Pfdhfr (N51I, C59R, S108N, I164L) and Pfdhps (A437G, K540E) mutations

Countries

Burkina Faso

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026